Align Technology, Inc. and 3Shape announced that 3Shape’s TRIOS® Standard, TRIOS Color and TRIOS 3 scanners will be able to be used for Invisalign® case submissions upon completion of the final validation process expected in Q4 this year. This will enable Invisalign providers with a 3Shape TRIOS intraoral scanner and TRIOS software upgrade 220.127.116.11 or higher to submit a full arch digital impression in place of a traditional PVS impression as part of the Invisalign case submission process. The companies also announced a collaborative agreement to enhance the existing STL export workflow with iTero® scanners and laboratory partners using 3Shape Dental System™ Software, which will enable improved consistency for customers using the workflow.
Align Technology supports an open system approach to digital impressions and continues to work with intraoral scanning companies interested in developing interoperability for use with Invisalign treatment. 3Shape TRIOS customers who are interested in becoming an Invisalign trained provider can find further information on training courses at http://provider.invisalign.com for North America and www.invisalign.eu for international regions.
“We are excited to expand our collaboration with 3Shape to provide both Invisalign and iTero customers with improved digital treatment workflows,” said Mr. Raphael Pascaud, Align Technology Chief Marketing, Portfolio, and Business Development Officer.
“We are very excited about the cooperation with Align Technology. Both companies seek to provide the best treatment opportunities for patients,” says Allan Junge Hyldal, Vice President, 3Shape Orthodontics. “By working together to make Invisalign treatment available for TRIOS users, we take a collective step forward in expanding treatment choices for patients and doctors.”
3Shape TRIOS customers can find further information at www.3shape.com/Invisalign or may contact their sales representative or local distributor for more information about 3Shape TRIOS connectivity for Invisalign case submission, which is expected to be available in Q4.